NCT03334552

Identification of Broadly HIV-1 Neutralizing Antibodies (bNAb) in HIV-infected Patients in Mbeya, Tanzania.

• Status: Unknown
• Phase: —
• Study type: Observational
• Enrollment: 500 (actual)
• Sponsor: Michael Hoelscher · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

In natural HIV disease, a small fraction (1-2%) of infected individuals develops exceptionally high titres of HIV-1 neutralizing serum activity. Antibodies isolated from these individuals have been shown to be highly active against a broad range of different HIV strains and are therefore called broadly neutralizing antibodies (bNAbs). These antibodies are in fact able to prevent (S)HIV infection in animal models and therefore of great interest for the development of an HIV vaccine. Information of neutralizing antibodies in patients from Africa is still scarce and would be of great value in the development of adapted HIV vaccine strategies in these regions. This study aims to investigate African HIV-infected individuals, who have developed neutralizing antibodies using highly specialized laboratory methodologies.

Conditions

• HIV/AIDS

Timeline

• Start date: 2017-10-15
• Primary completion: 2024-05-01
• Completion: 2024-08-01
• First posted: 2017-11-07
• Last updated: 2023-11-28

Locations

1 site across 1 country: Tanzania